BPC-157 vs TB-500: How the Two Differ
Two different molecules with different literatures, sold as one healing stack. Structure, human data, legal status and WADA bans, side by side.
The short version
BPC-157 and TB-500 are different molecules with different research behind them, though marketing often blurs them into a single healing stack. Neither has an approved human therapy package, so compare structure, evidence and legal status separately.
- They are not the same peptide and do not share one evidence base.
- Stacking protocols online come from practice, not from a trial of the pair.
- Both sit outside approved medicine in the US consumer research-chemical market.
BPC-157 and TB-500 are often talked about as two versions of the same idea. They are different molecules with different research behind them, and each has its own reasons people find it interesting.
Side by side
| BPC-157 | TB-500 | |
|---|---|---|
| What the name means | BPC = body protection compound; 157 is a serial designation. A researcher label, not a demonstrated effect | TB is generally read as thymosin beta. The name points at a protein this is only a fragment of - see the trap below |
| What it is | Synthetic 15-aa peptide (gastric-derived sequence lineage) | Synthetic 7-aa fragment (Ac-LKKTETQ), not full Tβ4 |
| Human efficacy | Reviews: efficacy not confirmed in humans; not approved | No published human RCT of the fragment I could locate |
| Common trap | Over-reading rodent work | Citing full-length thymosin beta-4 as if it were TB-500 |
| WADA 2026 | S0 Non-Approved Substances | S2.3 Tβ4 and derivatives e.g. TB-500 |
| US approval | Not FDA-approved | Not FDA-approved |
BPC-157 in one paragraph
BPC-157 has a large and consistently positive rodent literature on tissue healing. A 2019 review says efficacy is yet to be confirmed in humans. Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references below A 2025 review says it is not approved because comprehensive clinical studies are lacking. Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2)., in the references below Mechanistic and animal work keeps coming out, but that is not a finished human evidence package. Hsieh 2017 - Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333., in the references below
TB-500 in one paragraph
TB-500 is not thymosin beta-4. It is a short acetylated fragment. Much of the research shared under the TB-500 name is on the 43-aa protein, which does not automatically carry over to the fragment. The most direct animal test under the TB-500 name is encouraging. In a rat Achilles tendon study, TB-500 significantly improved tendon strength, while BPC-157 improved it only numerically. Biçer 2026 - Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837., in the references below
Evidence levels
BPC-157
Small or uncontrolled human studies. Too little to settle the question either way. Extensive preclinical work; human clinical package insufficient for approval per recent review language; one historical human RCT context exists in the wider literature but is not a modern efficacy program.
TB-500
Studied in cells or animals. No controlled trials in humans. Fragment frequently confused with full-length Tβ4; no published human RCT of the heptapeptide for tissue-repair indications located.
Stacking
The BPC + TB stack is widely used. The only study of the pair, in rats, found the combination added nothing over TB-500 alone. Biçer 2026 - Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837., in the references below I do not recommend stacking unapproved research chemicals. The Wolverine stack page covers what people who use it report.
Related
The pair is sold as the Wolverine stack.
Common questions
Is BPC-157 the same as TB-500?
No. BPC-157 is a synthetic 15-amino-acid peptide. TB-500 is a synthetic 7-amino-acid fragment related to thymosin beta-4. They are different molecules with different literature.
Can you stack BPC-157 and TB-500?
I do not recommend stacking unapproved research chemicals. Many people combine them as the Wolverine stack. The only study of the pair, in rats, found the combination added nothing over TB-500 alone. Neither has a human trial behind it as a therapy.
Which is better for healing?
Neither has the kind of human clinical package that would let a careful reader declare a winner for injury healing. BPC-157 has a large rodent literature; TB-500 did better than BPC-157 in one rat tendon study, and is frequently confused with full-length thymosin beta-4.
References (6 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
- 2.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
- 3.Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.StudyPMID 27847966
- 4.Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837.StudyPMID 42542926
- 5.WADA 2026 Prohibited List - BPC-157 under S0; Thymosin-ß4 and derivatives e.g. TB-500 under S2.3 (national anti-doping agency mirror, PDF).- World Anti-Doping Agency (mirrored by the Jamaica Anti-Doping Commission)regulatory
- 6.Wikipedia - TB-500. Secondary source for Ac-LKKTETQ structure and fragment-versus-parent distinction.- Wikipediaother